Childhood CancerHMNCT04764695
Body Composition and Nutritional Status in Pediatric Patients With Hematological Malignancies
A study testing D2O dilution technique in people with Childhood Cancer and Child Malnutrition, run by Universidad de Sonora at 1 site in Mexico.
Trial summary
Introduction: Annually 400,000 children are diagnosed with cancer in the world. Approximately 90% live in low/middle-income countries, with survival rates of 10-30%. In Mexico, children and adolescents' hospital admissions for cancer are mainly leukemias (46%), being acute lymphoblastic leukemia (ALL) the most common. Read more about this study
- Who is it for?
- Ages 2 to 14 years
- Conditions the study is for
- Childhood Cancer, Child Malnutrition, Childhood Obesity
- What is being tested?
- D2O dilution technique
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 38 participants
- Where
- 1 siteMexico
- Study dates
- 30 Jan 2023to 30 Nov 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 2 to 14 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Patients in remission stage (4 - 6 weeks)
- Life expectancy> 6 months and sufficient general conditions according to scales (Lansky ≥ 50 points for children <16 years)
- Histopathological/molecular clinical confirmation of the HM diagnosis
- Signature of the consent by the relative or legal guardian of the patient and as well as the consent informed by the patient.
Who cannot join
- Pathological conditions that can alter body composition (diabetes, hypothyroidism, among others)
- Patients with sepsis that causes hemodynamic compromise and cannot be evaluated
- Severely ill patients unable to participate in baseline measurements
- Relapsed patients
- Patients with developmental problems of a genetic order as well as innate errors of metabolism
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Evaluation of Body Composition and Nutritional Status in Pediatric Patients With Hematological Malignancies
Introduction: Annually 400,000 children are diagnosed with cancer in the world. Approximately 90% live in low/middle-income countries, with survival rates of 10-30%. In Mexico, children and adolescents' hospital admissions for cancer are mainly leukemias (46%), being acute lymphoblastic leukemia (ALL) the most common. Half of ALL patients have an altered nutritional status at the time of diagnosis. Nutritional assessment is performed using conventional anthropometric measures, which are not sensitive to changes in fat-free mass and fat mass (FFM and FFM). Our objective is to evaluate the body composition and nutritional status in pediatric patients with HM. This is a pre-test/post-test clinical trial. Children 2-14 y olds diagnosed with leukemia, myeloma and lymphoma in any stage of oncological treatment will participate. The nutritional status will be evaluated using questionnaires and body composition. Measurements will occur at the enrrollment of the study and 6 months after.
Read the detailed description
JUSTIFICATION Nutritional assessment of cancer patients is usually performed using conventional anthropometric techniques, which are not sensitive to short-term changes and do not reflect changes in the FFM, FM, and hydration status. Assessing body composition using reference techniques such as deuterium oxide dilution (DOD), and also using field methods (BIA and anthropometry), which are more accessible in clinical practice, can detect short-term changes in children and adolescents with HM.
In cancer patients, protein and muscle stores are frequently affected; an increase in FM and a decrease in FFM were observed within the first 6 months of antineoplastic treatment. The DOD technique identifies three compartments (total body water, FFM, and FM). Similar changes in body composition are seen in patients with breast cancer; the work carried out by Limón-Miró et al; where it was observed that an individualized nutritional intervention preserved FFM while reducing FM, both associated with quality of life and survival in breast cancer patients. This highlights the importance of specialized nutritional and body composition evaluations in the comprehensive treatment of cancer patients; in children and adolescents with HM, monitoring body composition combined with a nutrition intervention, could reduce the deterioration of FFM and provide a window to assess prognosis, clinical outcome, and survival of HM pediatric patients.
HYPOTHESES The body composition (fat and fat-free mass) and nutritional status of pediatric patients with HM in active treatment will be different at the beginning vs. the end of the study (6 months), in addition to showing differences against the healthy reference population.
GENERAL OBJECTIVE To evaluate changes in body composition and nutritional status in pediatric patients with HM under active treatment.
SPECIFIC OBJECTIVES
- To evaluate nutritional status using anthropometric and dietary indicators at the beginning and 6 months after the intervention.
- To assess fat mass and fat-free mass using reference and field techniques, at baseline and 6 months after the intervention.
- To establish a protocol on monitoring nutrition status and body composition that can be applied routinely in clinical practice.
METHODOLOGY Study design This is a pre-test/post-test design. Children from 2 to 14 years old with a diagnosis of HM two areas of Mexico (Hermosillo, Sonora / Guadalajara, Jalisco) will participate.
Sample size: To determine the sample size, we will work on the assumptions of a standard deviation (SD) of Fat-Free Mass (FFM) of 2.19 Kg, with a Variance of 4.8 Kg, a Zα of 1.96 for a p = 0.05, with a mean difference (Ԁ) of 1 Kg. The sample size was calculated considering the Beta error of 20% (B = 0.84), depending on the availability of the number of patients who agreed to participate, as well as those excluded by established criteria. Based on the data mentioned, the estimated sample size calculation is 38 participants, as detailed in the following equation.
N = ((Zα + Zβ) ^ 2 〖(DE)〗 ^ 2) / 〖(d)〗 ^ 2 = 38 participants Clinical record: The principles of the Official Mexican Norm (NOM) NOM-024-SSA3-201 will be followed, which establishes the functional objectives and functionalities that must be followed in the use of electronic clinical records. For this purpose, a confidential file number will be assigned, so that when analyzing the biological samples or data collected in the field, no access will be given to the names, address, telephone number, or related information that may be exposed to the participant.
Screening: Predictive screening will be used for the "Nutrition Screening Tool For Childhood Cancer (SCAN)" which consists of 6 questions. This tool identifies the need for a nutritional intervention according to the symptoms of the patients who classify at risk of malnutrition. Screening should be applied to all study subjects at each consultation or weekly to patients who are hospitalized since they are at high risk of malnutrition at the time of diagnosis and increases in the stages of treatment. The Lansky pediatric scale will also be applied, which allows evaluating the general condition of the patient, representing the degree of autonomy in the activities of daily life. In addition, the PedsQL Cancer Module © will be used, which is derived from the Pediatric Quality of Life Questionnaire (PedsQL), which is a generic instrument designed for children and parents to assess the quality of life as a self-report.
Dietary evaluation: The ENSANUT frequency questionnaire will be applied for the respective age groups: preschoolers, schoolchildren, and adolescents.
Anthropometry Weight and height: Body weight will be measured (electronic scale with 0.150 + 0.05 kg scales) or child scale (0-20 kg). Height will be measured by SECA stadiometers or infantometers, as required to the nearest 0.1 cm.
Mid-upper arm circumference (MUAC): This measure allows the identification of malnutrition in children under 5 years of age without taking weight, height, and age, by measuring the arm circumference at its midpoint.
Tricipital skinfold (TSF): With the participant standing, with the feet together, the shoulders relaxed and the arms hanging relaxed at the sides. The examiner will stand on the right side of the patient and place the top point on the back surface of the arm in the same area as the midpoint marked for the arm circumference. The skin fold of the skin and subcutaneous adipose tissue will be gently grasped with the thumb and index finger, approximately 1.0 cm above the point where the skin was scored, with the skin fold parallel to the longitudinal axis of the upper arm. The jaws of the calipers will be placed at the level that the skin was marked, these should be positioned perpendicular to the length of the fold. The skinfold will be held gently and the skinfold thickness will be measured to the nearest 1mm.
Waist circumference (WC): The waist circumference will be measured with a retractable tape at the level of the umbilical scar in a standing position and after exhaling.
All measurements will be processed by the Anthro software of the World Health Organization, for the calculation of nutritional indices such as Z score of weight/age, height/age, and weight/height in children <60 months, BMI-age- sex, and height/age in children> 60 months. A physical examination will be performed to observe signs of malnutrition (loss of subcutaneous fat, muscle wasting, edema, etc.).
Body composition Deuterium oxide dilution: Total body water will be measured by dilution of deuterium oxide (DOD) using Fourier transform infrared spectroscopy (FTIR) with a saliva sample. The doses of deuterium will be those recommended for field studies by the International Atomic Energy Agency (an amount that does not represent a risk for minors).
The measurement will be taken once the patient has gone to the bathroom, sterile material will be used taking care of the cleanliness and safety of the personnel in charge of the measurement. A pre-dose saliva sample will be taken, once the dose is calculated by the patient's weight, the DOD will be administered, this should be taken with syringe to avoid spilling the dose. After 3 hours, a post-dose saliva sample will be taken, at the time of calculation, it will be taken into account if the patient ingested extra fluids.
Electrical bioimpedance (BIA): BIA is considered a simple, fast, and non-invasive technique that allows the estimation of total body water (TBW), fat-free mass (FFM), and, by difference, fat mass (FM). The patient must be in the supine position at the time of measurement for at least 5 minutes before starting. 4 electrodes will be placed on its left ends, two on the hand and two on the foot, 5 cm away from each other, a current of 50 mHz is administered, then a resistance and reactance reading is taken to obtain the result of the test. impedance, following the standardized methodology.
For the study population, it is proposed to use the equation validated in the child population proposed by Ramírez E., et al. In this way, when knowing the FFM, the FM will be estimated by difference with the total body weight.
FFM(kg) = 0.661 x Ht2 / R + 0.200 x Wt - 0.320 Where Ht is height in cm squared, R is resistance, and Wt is weight in kg. Individualized nutritional intervention
Statistic analysis Descriptive statistics will be used using NCSS v11. To evaluate the effectiveness of the intervention, the t-student test or non-parametric tests will be performed depending on the distribution of the data. For BIA an algorithm will be used to predict total body water for the calculation of FFM and FM compared to the results of dilution with deuterium. Intention-to-treat analysis will also be performed, which should be seen more as a global strategy for the design, execution, and analysis of clinical trials, rather than solely as an alternative analysis.
- Conditions
- Childhood Cancer, Child Malnutrition, Childhood Obesity
- Being tested
- D2O dilution technique
- Keywords
- Children, Body Composition, Nutrition
- Medical subject headings
- Neoplasms, Child Nutrition Disorders, Pediatric Obesity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
D2O dilution techniqueDiagnostic test
Body composition will be measured with the deuterium dilution technique and electrical bioimpedance, as well as anthropometric indicators at the beginning and 6 months later.
| Study group | Role | What they receive |
|---|---|---|
| Patients diagnosed with HM | Experimental | As it is a pre-test / post-test design, the child himself will be the control at the end of the study. Additionally, children without ALL of the same age and sex will be taken as reference. The potential of including paired measurements against healthy children for external control is analyzed. Receives: Diagnostic Test: D2O dilution technique |
What is being measured
The primary outcome is the main question the study is designed to answer.
FFM 1
Fat free mass in kilograms (Kg)
Measured: at enrrollment
FFM 2
Fat free mass in kilograms (Kg)
Measured: 6 months
FM 1
Fat mass in kilograms (Kg)
Measured: at enrrollment
FM 2
Fat mass in kilograms (Kg)
Measured: 6 months
TBW 1
Total body water in kilograms (Kg)
Measured: at enrrollment
TBW 2
Total body water in kilograms (Kg)
Measured: 6 months
Secondary outcomes (8)
BMI
Body mass index for age in Kg/m^2
Measured: through study duration, an average of 6 months, once a month
Weight
Weight in kilograms (Kg)
Measured: through study duration, an average of 6 months, once a month
MUAC
Mid arm muscle circumference in centimeters (cm)
Measured: through study duration, an average of 6 months, once a month
Tricep skin fold (TSK)
Tricep skinfold in milimeters (mm)
Measured: through study duration, an average of 6 months, once a month
WC
Waist circumference in centimeters (cm)
Measured: through study duration, an average of 6 months, once a month
R
Resistance in Ohms
Measured: through study duration, an average of 6 months, once a month
Xc
Reactance in Ohms
Measured: through study duration, an average of 6 months, once a month
Height
Height in cm
Measured: through study duration, an average of 6 months, once a month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Feb 2021
- Study start30 Jan 2023
- Primary completion30 Aug 2024
- Study completion30 Nov 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (65)Papers the sponsor has linked to this study.
- Other trials for Childhood CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Screening
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Clinical trial with a pre-test/post-test design. Intervention group: Children and adolescents between 2 and 14 years old with a diagnosis of HM in any treatment stage who agree to participate in the project with the approval of their legal guardian. Control group: Being a pre-test/post-test design, the same child will be the control at the end of the intervention. Additionally, children without ALL of the same age and sex will be taken as reference. The potential of including paired measurements against healthy children for external control is analyzed.
- Masking
- None (open label)
- Enrolment
- 38 participants (actual)
Sponsor and investigators
- Lead sponsor
- Universidad de Sonora
- Sponsor type
- University, hospital or other
- Collaborators
- International Atomic Energy Agency, Hospital Civil de Guadalajara, Centro de Investigación en Alimentación y Desarrollo A.C.
- Responsible party
- Principal investigator, Verónica López Teros, PhD, Universidad de Sonora
- Investigators
- Veronica López Teros, PhD, Study director, Universidad de Sonora
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04764695
- Sponsor's protocol ID
- USonora
- Acronym
- HM
- Status last verified
- Dec 2024
- First submitted
- 10 Feb 2021
- Last updated
- 6 Dec 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Ward EJ, Henry LM, Friend AJ, Wilkins S, Phillips RS. Nutritional support in children and young people with cancer undergoing chemotherapy. Cochrane Database Syst Rev. 2015 Aug 24;2015(8):CD003298. doi: 10.1002/14651858.CD003298.pub3.
PubMed 26301790Cohen JE, Wakefield CE, Cohn RJ. Nutritional interventions for survivors of childhood cancer. Cochrane Database Syst Rev. 2016 Aug 22;2016(8):CD009678. doi: 10.1002/14651858.CD009678.pub2.
PubMed 27545902Francis DK, Smith J, Saljuqi T, Watling RM. Oral protein calorie supplementation for children with chronic disease. Cochrane Database Syst Rev. 2015 May 27;2015(5):CD001914. doi: 10.1002/14651858.CD001914.pub2.
PubMed 26014160Ladas EJ, Orjuela M, Stevenson K, Cole PD, Lin M, Athale UH, Clavell LA, Leclerc JM, Michon B, Schorin MA, Welch JG, Asselin BL, Sallan SE, Silverman LB, Kelly KM. Dietary intake and childhood leukemia: The Diet and Acute Lymphoblastic Leukemia Treatment (DALLT) cohort study. Nutrition. 2016 Oct;32(10):1103-1109.e1. doi: 10.1016/j.nut.2016.03.014. Epub 2016 Mar 28.
PubMed 27318855Ramirez E, Valencia ME, Moya-Camarena SY, Aleman-Mateo H, Mendez RO. Four-compartment model and validation of deuterium dilution technique to estimate fat-free mass in Mexican youth. Nutrition. 2009 Feb;25(2):194-9. doi: 10.1016/j.nut.2008.08.007. Epub 2008 Oct 23.
PubMed 18947978Yang HR, Choi HS. A prospective study on changes in body composition and fat percentage during the first year of cancer treatment in children. Nutr Res Pract. 2019 Jun;13(3):214-221. doi: 10.4162/nrp.2019.13.3.214. Epub 2019 Mar 13.
PubMed 31214289De Palo T, Messina G, Edefonti A, Perfumo F, Pisanello L, Peruzzi L, Di Iorio B, Mignozzi M, Vienna A, Conti G, Penza R, Piccoli A. Normal values of the bioelectrical impedance vector in childhood and puberty. Nutrition. 2000 Jun;16(6):417-24. doi: 10.1016/s0899-9007(00)00269-0.
PubMed 10869896Cameron N. Essential anthropometry: Baseline anthropometric methods for human biologists in laboratory and field situations. Am J Hum Biol. 2013 May-Jun;25(3):291-9. doi: 10.1002/ajhb.22388. No abstract available.
PubMed 23606226Jones PJ, Leatherdale ST. Stable isotopes in clinical research: safety reaffirmed. Clin Sci (Lond). 1991 Apr;80(4):277-80. doi: 10.1042/cs0800277.
PubMed 1851061Abrams SA. Assessing mineral metabolism in children using stable isotopes. Pediatr Blood Cancer. 2008 Feb;50(2 Suppl):438-41; discussion 451. doi: 10.1002/pbc.21417.
PubMed 18064657Wauben IP, Atkinson SA, Bradley C, Halton JM, Barr RD. Magnesium absorption using stable isotope tracers in healthy children and children treated for leukemia. Nutrition. 2001 Mar;17(3):221-4. doi: 10.1016/s0899-9007(00)00507-4.
PubMed 11312063Egnell C, Ranta S, Banerjee J, Merker A, Niinimaki R, Lund B, Mogensen PR, Jonsson OG, Vaitkeviciene G, Lepik K, Forslund A, Heyman M, Harila-Saari A. Impact of body mass index on relapse in children with acute lymphoblastic leukemia treated according to Nordic treatment protocols. Eur J Haematol. 2020 Dec;105(6):797-807. doi: 10.1111/ejh.13517. Epub 2020 Sep 20.
PubMed 32909636Brinksma A, Roodbol PF, Sulkers E, Kamps WA, de Bont ES, Boot AM, Burgerhof JG, Tamminga RY, Tissing WJ. Changes in nutritional status in childhood cancer patients: a prospective cohort study. Clin Nutr. 2015 Feb;34(1):66-73. doi: 10.1016/j.clnu.2014.01.013. Epub 2014 Jan 23.
PubMed 24508424Chincesan MI, Marginean CO, Voidazan S. Assessment of Body Composition in a Group of Pediatric Patients With Cancer: A Single Romanian Center Experience. J Pediatr Hematol Oncol. 2016 Oct;38(7):e217-22. doi: 10.1097/MPH.0000000000000586.
PubMed 27164536Jaime-Perez JC, Gonzalez-Llano O, Herrera-Garza JL, Gutierrez-Aguirre H, Vazquez-Garza E, Gomez-Almaguer D. Assessment of nutritional status in children with acute lymphoblastic leukemia in Northern Mexico: A 5-year experience. Pediatr Blood Cancer. 2008 Feb;50(2 Suppl):506-8; discussion 517. doi: 10.1002/pbc.21397.
PubMed 18064642
Study at a glance
From the registry record, last updated by the sponsor on 6 Dec 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of Body Composition and Nutritional Status in Pediatric Patients With Hematological Malignancies
- ClinicalTrials.gov ID
- NCT04764695
- Acronym / sponsor ID
- HM / USonora
- Conditions
- Childhood Cancer, Child Malnutrition, Childhood Obesity
- Keywords
- Children, Body Composition, Nutrition
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 38 participants (actual)
- Lead sponsor
- Universidad de SonoraUniversity, hospital or other
- Collaborators
- International Atomic Energy Agency, Hospital Civil de Guadalajara, Centro de Investigación en Alimentación y Desarrollo A.C.
- Study start
- 30 Jan 2023 (actual)
- Primary completion
- 30 Aug 2024 (actual)
- Study completion
- 30 Nov 2024 (actual)
- First posted
- 21 Feb 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Introduction: Annually 400,000 children are diagnosed with cancer in the world. Approximately 90% live in low/middle-income countries, with survival rates of 10-30%. In Mexico, children and adolescents' hospital admissions for cancer are mainly leukemias (46%), being acute lymphoblastic leukemia (ALL) the most common. Half of ALL patients have an altered nutritional status at the time of diagnosis. Nutritional assessment is performed using conventional anthropometric measures, which are not sensitive to changes in fat-free mass and fat mass (FFM and FFM). Our objective is to evaluate the body composition and nutritional status in pediatric patients with HM. This is a pre-test/post-test clinical trial. Children 2-14 y olds diagnosed with leukemia, myeloma and lymphoma in any stage of oncological treatment will participate. The nutritional status will be evaluated using questionnaires and body composition. Measurements will occur at the enrrollment of the study and 6 months after.
Detailed description
JUSTIFICATION Nutritional assessment of cancer patients is usually performed using conventional anthropometric techniques, which are not sensitive to short-term changes and do not reflect changes in the FFM, FM, and hydration status. Assessing body composition using reference techniques such as deuterium oxide dilution (DOD), and also using field methods (BIA and anthropometry), which are more accessible in clinical practice, can detect short-term changes in children and adolescents with HM.
In cancer patients, protein and muscle stores are frequently affected; an increase in FM and a decrease in FFM were observed within the first 6 months of antineoplastic treatment. The DOD technique identifies three compartments (total body water, FFM, and FM). Similar changes in body composition are seen in patients with breast cancer; the work carried out by Limón-Miró et al; where it was observed that an individualized nutritional intervention preserved FFM while reducing FM, both associated with quality of life and survival in breast cancer patients. This highlights the importance of specialized nutritional and body composition evaluations in the comprehensive treatment of cancer patients; in children and adolescents with HM, monitoring body composition combined with a nutrition intervention, could reduce the deterioration of FFM and provide a window to assess prognosis, clinical outcome, and survival of HM pediatric patients.
HYPOTHESES The body composition (fat and fat-free mass) and nutritional status of pediatric patients with HM in active treatment will be different at the beginning vs. the end of the study (6 months), in addition to showing differences against the healthy reference population.
GENERAL OBJECTIVE To evaluate changes in body composition and nutritional status in pediatric patients with HM under active treatment.
SPECIFIC OBJECTIVES
- To evaluate nutritional status using anthropometric and dietary indicators at the beginning and 6 months after the intervention.
- To assess fat mass and fat-free mass using reference and field techniques, at baseline and 6 months after the intervention.
- To establish a protocol on monitoring nutrition status and body composition that can be applied routinely in clinical practice.
METHODOLOGY Study design This is a pre-test/post-test design. Children from 2 to 14 years old with a diagnosis of HM two areas of Mexico (Hermosillo, Sonora / Guadalajara, Jalisco) will participate.
Sample size: To determine the sample size, we will work on the assumptions of a standard deviation (SD) of Fat-Free Mass (FFM) of 2.19 Kg, with a Variance of 4.8 Kg, a Zα of 1.96 for a p = 0.05, with a mean difference (Ԁ) of 1 Kg. The sample size was calculated considering the Beta error of 20% (B = 0.84), depending on the availability of the number of patients who agreed to participate, as well as those excluded by established criteria. Based on the data mentioned, the estimated sample size calculation is 38 participants, as detailed in the following equation.
N = ((Zα + Zβ) ^ 2 〖(DE)〗 ^ 2) / 〖(d)〗 ^ 2 = 38 participants Clinical record: The principles of the Official Mexican Norm (NOM) NOM-024-SSA3-201 will be followed, which establishes the functional objectives and functionalities that must be followed in the use of electronic clinical records. For this purpose, a confidential file number will be assigned, so that when analyzing the biological samples or data collected in the field, no access will be given to the names, address, telephone number, or related information that may be exposed to the participant.
Screening: Predictive screening will be used for the "Nutrition Screening Tool For Childhood Cancer (SCAN)" which consists of 6 questions. This tool identifies the need for a nutritional intervention according to the symptoms of the patients who classify at risk of malnutrition. Screening should be applied to all study subjects at each consultation or weekly to patients who are hospitalized since they are at high risk of malnutrition at the time of diagnosis and increases in the stages of treatment. The Lansky pediatric scale will also be applied, which allows evaluating the general condition of the patient, representing the degree of autonomy in the activities of daily life. In addition, the PedsQL Cancer Module © will be used, which is derived from the Pediatric Quality of Life Questionnaire (PedsQL), which is a generic instrument designed for children and parents to assess the quality of life as a self-report.
Dietary evaluation: The ENSANUT frequency questionnaire will be applied for the respective age groups: preschoolers, schoolchildren, and adolescents.
Anthropometry Weight and height: Body weight will be measured (electronic scale with 0.150 + 0.05 kg scales) or child scale (0-20 kg). Height will be measured by SECA stadiometers or infantometers, as required to the nearest 0.1 cm.
Mid-upper arm circumference (MUAC): This measure allows the identification of malnutrition in children under 5 years of age without taking weight, height, and age, by measuring the arm circumference at its midpoint.
Tricipital skinfold (TSF): With the participant standing, with the feet together, the shoulders relaxed and the arms hanging relaxed at the sides. The examiner will stand on the right side of the patient and place the top point on the back surface of the arm in the same area as the midpoint marked for the arm circumference. The skin fold of the skin and subcutaneous adipose tissue will be gently grasped with the thumb and index finger, approximately 1.0 cm above the point where the skin was scored, with the skin fold parallel to the longitudinal axis of the upper arm. The jaws of the calipers will be placed at the level that the skin was marked, these should be positioned perpendicular to the length of the fold. The skinfold will be held gently and the skinfold thickness will be measured to the nearest 1mm.
Waist circumference (WC): The waist circumference will be measured with a retractable tape at the level of the umbilical scar in a standing position and after exhaling.
All measurements will be processed by the Anthro software of the World Health Organization, for the calculation of nutritional indices such as Z score of weight/age, height/age, and weight/height in children <60 months, BMI-age- sex, and height/age in children> 60 months. A physical examination will be performed to observe signs of malnutrition (loss of subcutaneous fat, muscle wasting, edema, etc.).
Body composition Deuterium oxide dilution: Total body water will be measured by dilution of deuterium oxide (DOD) using Fourier transform infrared spectroscopy (FTIR) with a saliva sample. The doses of deuterium will be those recommended for field studies by the International Atomic Energy Agency (an amount that does not represent a risk for minors).
The measurement will be taken once the patient has gone to the bathroom, sterile material will be used taking care of the cleanliness and safety of the personnel in charge of the measurement. A pre-dose saliva sample will be taken, once the dose is calculated by the patient's weight, the DOD will be administered, this should be taken with syringe to avoid spilling the dose. After 3 hours, a post-dose saliva sample will be taken, at the time of calculation, it will be taken into account if the patient ingested extra fluids.
Electrical bioimpedance (BIA): BIA is considered a simple, fast, and non-invasive technique that allows the estimation of total body water (TBW), fat-free mass (FFM), and, by difference, fat mass (FM). The patient must be in the supine position at the time of measurement for at least 5 minutes before starting. 4 electrodes will be placed on its left ends, two on the hand and two on the foot, 5 cm away from each other, a current of 50 mHz is administered, then a resistance and reactance reading is taken to obtain the result of the test. impedance, following the standardized methodology.
For the study population, it is proposed to use the equation validated in the child population proposed by Ramírez E., et al. In this way, when knowing the FFM, the FM will be estimated by difference with the total body weight.
FFM(kg) = 0.661 x Ht2 / R + 0.200 x Wt - 0.320 Where Ht is height in cm squared, R is resistance, and Wt is weight in kg. Individualized nutritional intervention
Statistic analysis Descriptive statistics will be used using NCSS v11. To evaluate the effectiveness of the intervention, the t-student test or non-parametric tests will be performed depending on the distribution of the data. For BIA an algorithm will be used to predict total body water for the calculation of FFM and FM compared to the results of dilution with deuterium. Intention-to-treat analysis will also be performed, which should be seen more as a global strategy for the design, execution, and analysis of clinical trials, rather than solely as an alternative analysis.
Study design
- Primary purpose
- Screening
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Clinical trial with a pre-test/post-test design. Intervention group: Children and adolescents between 2 and 14 years old with a diagnosis of HM in any treatment stage who agree to participate in the project with the approval of their legal guardian. Control group: Being a pre-test/post-test design, the same child will be the control at the end of the intervention. Additionally, children without ALL of the same age and sex will be taken as reference. The potential of including paired measurements against healthy children for external control is analyzed.
| Arm | Type | Receives |
|---|---|---|
| Patients diagnosed with HM | Experimental | Diagnostic Test: D2O dilution techniqueAs it is a pre-test / post-test design, the child himself will be the control at the end of the study. Additionally, children without ALL of the same age and sex will be taken as reference. The potential of including paired measurements against healthy children for external control is analyzed. |
Who may qualify
- Ages
- 2 to 14 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (4 listed)
- Patients in remission stage (4 - 6 weeks)
- Life expectancy> 6 months and sufficient general conditions according to scales (Lansky ≥ 50 points for children <16 years)
- Histopathological/molecular clinical confirmation of the HM diagnosis
- Signature of the consent by the relative or legal guardian of the patient and as well as the consent informed by the patient.
Key exclusion criteria (5 listed)
- Pathological conditions that can alter body composition (diabetes, hypothyroidism, among others)
- Patients with sepsis that causes hemodynamic compromise and cannot be evaluated
- Severely ill patients unable to participate in baseline measurements
- Relapsed patients
- Patients with developmental problems of a genetic order as well as innate errors of metabolism
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| D2O dilution techniqueBody composition will be measured with the deuterium dilution technique and electrical bioimpedance, as well as anthropometric indicators at the beginning and 6 months later. | Diagnostic test | Patients diagnosed with HM |
Primary outcome
FFM 1
Time frame: at enrrollment
Fat free mass in kilograms (Kg)
FFM 2
Time frame: 6 months
Fat free mass in kilograms (Kg)
FM 1
Time frame: at enrrollment
Fat mass in kilograms (Kg)
FM 2
Time frame: 6 months
Fat mass in kilograms (Kg)
TBW 1
Time frame: at enrrollment
Total body water in kilograms (Kg)
TBW 2
Time frame: 6 months
Total body water in kilograms (Kg)
8 secondary outcomes
BMI
Time frame: through study duration, an average of 6 months, once a month
Weight
Time frame: through study duration, an average of 6 months, once a month
MUAC
Time frame: through study duration, an average of 6 months, once a month
Tricep skin fold (TSK)
Time frame: through study duration, an average of 6 months, once a month
WC
Time frame: through study duration, an average of 6 months, once a month
R
Time frame: through study duration, an average of 6 months, once a month
Xc
Time frame: through study duration, an average of 6 months, once a month
Height
Time frame: through study duration, an average of 6 months, once a month
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Dec 2024.
- Background: PubMed 26301790Ward EJ, Henry LM, Friend AJ, Wilkins S, Phillips RS. Nutritional support in children and young people with cancer undergoing chemotherapy. Cochrane Database Syst Rev. 2015 Aug 24;2015(8):CD003298. doi: 10.1002/14651858.CD003298.pub3.
- Background: PubMed 27545902Cohen JE, Wakefield CE, Cohn RJ. Nutritional interventions for survivors of childhood cancer. Cochrane Database Syst Rev. 2016 Aug 22;2016(8):CD009678. doi: 10.1002/14651858.CD009678.pub2.
- Background: PubMed 26014160Francis DK, Smith J, Saljuqi T, Watling RM. Oral protein calorie supplementation for children with chronic disease. Cochrane Database Syst Rev. 2015 May 27;2015(5):CD001914. doi: 10.1002/14651858.CD001914.pub2.
- Background: PubMed 27318855Ladas EJ, Orjuela M, Stevenson K, Cole PD, Lin M, Athale UH, Clavell LA, Leclerc JM, Michon B, Schorin MA, Welch JG, Asselin BL, Sallan SE, Silverman LB, Kelly KM. Dietary intake and childhood leukemia: The Diet and Acute Lymphoblastic Leukemia Treatment (DALLT) cohort study. Nutrition. 2016 Oct;32(10):1103-1109.e1. doi: 10.1016/j.nut.2016.03.014. Epub 2016 Mar 28.
- Background: PubMed 18947978Ramirez E, Valencia ME, Moya-Camarena SY, Aleman-Mateo H, Mendez RO. Four-compartment model and validation of deuterium dilution technique to estimate fat-free mass in Mexican youth. Nutrition. 2009 Feb;25(2):194-9. doi: 10.1016/j.nut.2008.08.007. Epub 2008 Oct 23.
- Background: PubMed 31214289Yang HR, Choi HS. A prospective study on changes in body composition and fat percentage during the first year of cancer treatment in children. Nutr Res Pract. 2019 Jun;13(3):214-221. doi: 10.4162/nrp.2019.13.3.214. Epub 2019 Mar 13.
- Background: PubMed 10869896De Palo T, Messina G, Edefonti A, Perfumo F, Pisanello L, Peruzzi L, Di Iorio B, Mignozzi M, Vienna A, Conti G, Penza R, Piccoli A. Normal values of the bioelectrical impedance vector in childhood and puberty. Nutrition. 2000 Jun;16(6):417-24. doi: 10.1016/s0899-9007(00)00269-0.
- Background: PubMed 23606226Cameron N. Essential anthropometry: Baseline anthropometric methods for human biologists in laboratory and field situations. Am J Hum Biol. 2013 May-Jun;25(3):291-9. doi: 10.1002/ajhb.22388. No abstract available.
- Background: PubMed 1851061Jones PJ, Leatherdale ST. Stable isotopes in clinical research: safety reaffirmed. Clin Sci (Lond). 1991 Apr;80(4):277-80. doi: 10.1042/cs0800277.
- Background: PubMed 18064657Abrams SA. Assessing mineral metabolism in children using stable isotopes. Pediatr Blood Cancer. 2008 Feb;50(2 Suppl):438-41; discussion 451. doi: 10.1002/pbc.21417.
- Background: PubMed 11312063Wauben IP, Atkinson SA, Bradley C, Halton JM, Barr RD. Magnesium absorption using stable isotope tracers in healthy children and children treated for leukemia. Nutrition. 2001 Mar;17(3):221-4. doi: 10.1016/s0899-9007(00)00507-4.
- Background: PubMed 32909636Egnell C, Ranta S, Banerjee J, Merker A, Niinimaki R, Lund B, Mogensen PR, Jonsson OG, Vaitkeviciene G, Lepik K, Forslund A, Heyman M, Harila-Saari A. Impact of body mass index on relapse in children with acute lymphoblastic leukemia treated according to Nordic treatment protocols. Eur J Haematol. 2020 Dec;105(6):797-807. doi: 10.1111/ejh.13517. Epub 2020 Sep 20.
- Individual participant dataSharing planned: No
Related trials for Childhood Cancer
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
RecruitingObservational study
Psychological Benefits of a Normalized Camping Experience for Children With Cancer
Pediatric Cancer
Recruiting
An Exploratory Study to Evaluate Immune Determinants of the Response to Adoptive Cell Therapy (ACT) in Solid and Hematologic Tumors
Solid Tumor, Adult, Solid Tumor, Childhood
RecruitingObservational study
The Decision To Enroll In Therapeutic Clinical Trials In A Pediatric Cancer Clinical Network
Knowledge, Attitudes, Practice
Recruiting
Facial Expression Awareness Training to Understand and Recognize Emotions
Survivors of Pediatric Brain Tumors, Pediatric Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Veronica López Teros, PhD study director
Universidad de Sonora
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing D2O dilution technique in people with Childhood Cancer and Child Malnutrition, run by Universidad de Sonora at 1 site in Mexico.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Dec 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Mexico. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
FFM 1 (time frame: at enrrollment). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04764695, which also lists 65 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Dec 2024.